VTV Therapeutics Inc. Class AVTVT
13F holders, Q4 2024 (December 31)17holders −3
1new positions
3sold out
$13.73avg. 13F price*
At the end of Q4 2024, 17 institutions reported holding VTV Therapeutics Inc. Class A (VTVT) in their 13F filings, down 3 from Q3 2024. 1 opened new positions and 3 sold out. The largest holders were Samsara Biocapital, LLC ($2.9M), FMR LLC ($2.4M) and Baker Bros. Advisors LP ($1.3M).
- Company
- VTV Therapeutics Inc. Class A
- CUSIP
- 918385204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $25K |
| Exits | 3 | $6K |
All 13F filers, Q3 2024 → Q4 2024: 10,192 shares bought and 475 shares sold, net +9,717 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Samsara Biocapital, LLC | 0.39% | No change | 206,784 | $2.9M |
| FMR LLC | 0.00% | No change | 178,200 | $2.4M |
| Baker Bros. Advisors LP | 0.01% | No change | 97,314 | $1.3M |
| Vanguard Group Inc. | 0.00% | No change | 41,558 | $566K |
| Geode Capital Management, LLC | 0.00% | Add +12.9% | 11,634 | $158K |
| UBS Group AG | 0.00% | Add +767.4% | 7,512 | $104K |
| BlackRock, Inc. | 0.00% | Add +0.5% | 4,773 | $66K |
| JPMorgan Chase & Co. | 0.00% | New | 1,803 | $25K |
| Morgan Stanley | 0.00% | Add +36.4% | 1,146 | $16K |
| Royal Bank of Canada | 0.00% | Add +29.4% | 383 | $5K |
| Osaic Holdings, Inc. | 0.00% | Reduce -4.5% | 170 | $2K |
| Activest Wealth Management | 0.00% | No change | 50 | $690 |
| Parallel Advisors, LLC | 0.00% | No change | 38 | $525 |
| Cornerstone Planning Group LLC | 0.00% | No change | 19 | $268 |
| Sunbelt Securities, Inc. | 0.00% | No change | 15 | $210 |
| BNP Paribas Financial Markets | 0.00% | No change | 9 | $124 |
| Bank of America Corp. | 0.00% | No change | 8 | $110 |
"% of holder's portfolio" is VTVT's weight in each manager's 13F, not the share of VTV Therapeutics Inc. Class A the manager owns.